Schultz SK, Andreasen NC. Schizophrenia. Lancet. 1999;353(9162):1425–30.

Article  CAS  PubMed  Google Scholar 

Institute of Health Metrics and Evaluation (IHME). Global Health Data Exchange (GHDx). http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019

Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–24.

Article  PubMed  Google Scholar 

Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195–203.

Article  PubMed  PubMed Central  Google Scholar 

Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatr. 2015;72(12):1172–81.

Article  Google Scholar 

Ran MS, Xiao Y, Fazel S, et al. Mortality and suicide in schizophrenia: 21-year follow-up in rural China. BJPsych Open. 2020;6(6): e121.

Article  PubMed  PubMed Central  Google Scholar 

Bareis N, Olfson M, Gerhard T, et al. Means of suicide among adults with schizophrenia across the life span. Schizophr Res. 2023;251:82–90.

Article  PubMed  Google Scholar 

Mothershed SM, Bullard JC. Preparation of fluorescein-labelled immune globulin for the identification of Treponema pallidum. Br J Vener Dis. 1968;44(3):201–7.

CAS  PubMed  PubMed Central  Google Scholar 

Nucifora FC Jr., Woznica E, Lee BJ, et al. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131: 104257.

Article  PubMed  Google Scholar 

Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30(3):286–97.

Article  CAS  PubMed  Google Scholar 

Boyer L, Falissard B, Nuss P, et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023;28(9):3709–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–80.

Article  PubMed  Google Scholar 

Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatr. 2017;74(7):686–93.

Article  Google Scholar 

Li Q, Li Y, Yang Y, et al. Efficacy and safety of once-monthly paliperidone palmitate long-acting injections in Chinese patients with early-, mid-, and late-phase schizophrenia: a post-hoc analysis of three phase 4 studies. CNS Drugs. 2025;39(8):795–805.

Article  PubMed  PubMed Central  Google Scholar 

Liu R, Liu C, Hu D, et al. An analysis of the clinical application of paliperidone palmitate injection based on real-world. Front Pharmacol. 2025;16:1501701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bai Z, Wang G, Cai S, et al. Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis. Schizophr Res. 2017;185:73–9.

Article  PubMed  Google Scholar 

Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatr. 2015;72(8):830–9.

Article  Google Scholar 

Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.

Article  CAS  PubMed  Google Scholar 

Al-Amrani S, Al-Jabri Z, Al-Zaabi A, et al. Proteomics: concepts and applications in human medicine. World J Biol Chem. 2021;12(5):57–69.

Article  PubMed  PubMed Central  Google Scholar 

Chandramouli K, Qian PY. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics 2009 Dec 8;2009:239204. https://doi.org/10.4061/2009/239204.

Davalieva K, Maleva Kostovska I, Dwork AJ. Proteomics research in schizophrenia. Front Cell Neurosci. 2016;10: 18.

Article  PubMed  PubMed Central  Google Scholar 

Ren X, Tan SM, Liu JX, et al. Research progress of transcriptomics and proteomics in schizophrenia. Zhonghua Yu Fang Yi Xue Za Zhi. 2023;57(10):1704–10.

CAS  PubMed  Google Scholar 

Cotter DR, Sabherwal S, Schubert KO. Chapter 25 - Proteomics for diagnostic and therapeutic blood biomarker discovery in schizophrenia and other psychotic disorders. In: Baune BT, editor. Personalized Psychiatry. San Diego: Academic Press; 2020. p. 307–17.

Chapter  Google Scholar 

Smith BJ, Brandão-Teles C, Zuccoli GS, et al. Protein succinylation and malonylation as potential biomarkers in schizophrenia. J Pers Med. 2022. https://doi.org/10.3390/jpm12091408.

Article  PubMed  PubMed Central  Google Scholar 

Dmitrieva E, Smirnova L, Seregin A, et al. Proteomic profile of serum from patients with schizophrenia spectrum disorders. PeerJ. 2022;10: e13907.

Article  PubMed  PubMed Central  Google Scholar 

Lee H, Kim M, Kim SH, et al. Proteomic profiling in the progression of psychosis: analysis of clinical high-risk, first episode psychosis, and healthy controls. J Psychiatr Res. 2024;169:264–71.

Article  PubMed  Google Scholar 

Rodrigues JE, Martinho A, Santa C, et al. Systematic review and meta-analysis of mass spectrometry proteomics applied to human peripheral fluids to assess potential biomarkers of schizophrenia. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23094917.

Article  PubMed  PubMed Central  Google Scholar 

Pisanu C, Severino G, Minelli A, et al. Biomarkers of treatment-resistant schizophrenia: a systematic review. Neuroscience Applied. 2024;3: 104059.

Article  PubMed  PubMed Central  Google Scholar 

Pillinger T, D’Ambrosio E, McCutcheon R, et al. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):776–94.

Article  CAS  PubMed  Google Scholar 

Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240–50.

Article  PubMed  PubMed Central  Google Scholar 

Strassnig M, Kotov R, Cornaccio D, et al. Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. Bipolar Disord. 2017;19(5):336–43.

Article  PubMed  PubMed Central  Google Scholar 

Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiaodong Peng H X HZ, Dong Jin, et al. Epidemiological features of severe mental disorders of Shenzhen in 2017. Modern Preventive Med. 2018;45(05): 777-80+88.

Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75(Suppl 1):8–14.

Article  PubMed  Google Scholar 

Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med. 2019;25(12):1843–50.

Article  CAS  PubMed  PubMed Central